Key facts
- This page summarizes Thomas Ciulla's Form 3 filing for Viridian Therapeutics, Inc.\DE (VRDN).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 12 Jan 2024, 16:31.
Thomas Ciulla - 03 Jan 2024 Form 3 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- VRDN
- Reported as of
- 03 Jan 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 12 Jan 2024, 16:31:56 UTC
- Prior SEC filing
- 20 Jan 2023
- Next SEC filing
- 07 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas Ciulla
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Ciulla filed Form 3 for Viridian Therapeutics, Inc.\DE (VRDN) on 12 Jan 2024.
Change
- Previous filing in this sequence was filed on 20 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRDN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 762
- Date
- 03 Jan 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRDN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $33.06
- Footnotes
- F1
VRDN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $28.22
- Footnotes
- F2
VRDN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 270,000
- Exercise price
- $13.76
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on February 17, 2024, with the remaining vesting in approximately equal monthly installments through February 17, 2027, subject to the Reporting Person's continued service to the Issuer.
Footnote F2
This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 8,333 of which have vested, with the remaining vesting in approximately equal monthly installments through April 25, 2027, subject to the Reporting Person's continued service to the Issuer.
Footnote F3
This option represents a right to purchase a total of 270,000 shares of the Issuer's common stock, 11,250 of which have vested, with the remaining vesting in approximately equal monthly installments through November 10, 2027, subject to the Reporting Person's continued service to the Issuer.